GO:0005171 hepatocyte growth factor receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005171 (hepatocyte growth factor receptor binding) is a molecular function describing the binding of a ligand to the hepatocyte growth factor receptor (MET).
• The primary ligand is hepatocyte growth factor (HGF), a disulfide-linked heterodimer that binds MET with high affinity and triggers receptor dimerization and activation.
• MET activation by HGF initiates downstream signaling through phosphatidylinositol 3-kinase (PI3K) and other pathways, regulating cell proliferation, survival, and motility.
• The interaction is regulated by ligand-induced ubiquitination and multimerization of MET, which control receptor trafficking and signaling duration.
• Dysregulated HGF-MET binding is implicated in cancer progression, making it a target for therapeutic inhibitors identified through computational and phytochemical studies.
• Bacterial agonists of the HGF receptor can stimulate hepatocyte proliferation and accelerate liver regeneration in preclinical models.
Description
Hepatocyte growth factor receptor binding (GO:0005171) is a molecular function that mediates the specific interaction between a ligand and the hepatocyte growth factor receptor, also known as MET. This binding event is the first step in a signaling cascade that controls fundamental cellular processes such as proliferation, survival, migration, and morphogenesis. The receptor is a receptor tyrosine kinase, and its activation by hepatocyte growth factor (HGF) is critical for embryonic development, tissue regeneration, and homeostasis. Researchers study this term to understand how extracellular cues are translated into intracellular signals and to identify therapeutic targets for diseases where MET signaling is dysregulated, including cancers and chronic liver diseases. The binding function is highly specific and is modulated by molecular features of both the ligand and the receptor, as revealed by molecular engineering and computational studies.
hepatocyte growth factor receptor binding At A Glance
| GO ID | GO:0005171 |
|---|---|
| GO term | hepatocyte growth factor receptor binding |
| Ontology | molecular_function |
| Synonym | hepatocyte growth factor, hepatocyte growth factor receptor ligand, HGF receptor binding |
| Major function | Binding to the hepatocyte growth factor receptor (MET) to initiate receptor activation and downstream signaling |
| Primary ligand | Hepatocyte growth factor (HGF), a disulfide-linked heterodimer |
| Receptor | MET (c-Met), a receptor tyrosine kinase |
| Downstream pathways | Phosphatidylinositol 3-kinase (PI3K) and other signaling cascades |
| Regulation | Ligand-induced ubiquitination and multimerization of MET |
What Is GO:0005171?
According to the Gene Ontology, GO:0005171 is defined as the binding to a hepatocyte growth factor receptor. In other words, it is the molecular function of a ligand (such as hepatocyte growth factor) physically interacting with the hepatocyte growth factor receptor (MET). This function is distinct from the downstream signaling events it triggers; it specifically describes the recognition and binding event at the molecular level.
Why Is hepatocyte growth factor receptor binding Important in Cell Biology?
GO:0005171 is important because it represents the molecular trigger for MET signaling, a pathway that is essential for normal development and tissue repair but is frequently hijacked in human diseases. Understanding the precise binding mechanism enables the design of inhibitors and agonists that can modulate MET activity for therapeutic benefit, as demonstrated by computational and experimental studies.
• Controls cell proliferation, survival, and migration through MET-mediated signaling.
• Essential for liver regeneration and tissue repair after injury.
• Dysregulated in many cancers, where aberrant HGF-MET binding drives tumor growth and metastasis.
• Provides a target for small-molecule inhibitors and phytochemicals with potential anticancer activity.
• Regulated by ubiquitination and multimerization, offering additional points for therapeutic intervention.
• Involved in embryonic development and organogenesis.
• Bacterial agonists can stimulate hepatocyte proliferation, suggesting applications in regenerative medicine.
• Molecular engineering studies have identified functional domains critical for binding specificity.
• Binding affinity and kinetics can be modeled computationally to guide drug discovery.
• The interaction is a paradigm for understanding receptor tyrosine kinase activation.
Molecular Mechanism of hepatocyte growth factor receptor binding
Ligand recognition and binding
In simple terms: HGF grabs onto MET like a key fitting into a lock.
Hepatocyte growth factor (HGF) is a disulfide-linked heterodimer that binds with high affinity to the extracellular domain of MET, the hepatocyte growth factor receptor. This binding is highly specific and involves multiple domains of both proteins, as shown by molecular engineering studies that identified functional domains in HGF and its receptor. Computational investigations have further characterized the interaction interface, revealing key residues that contribute to binding affinity and specificity.
Receptor dimerization and activation
In simple terms: When HGF binds, two MET molecules come together and switch each other on.
Binding of HGF to MET induces receptor dimerization, which is a prerequisite for activation of the intracellular tyrosine kinase domain. This dimerization leads to autophosphorylation of specific tyrosine residues in the kinase domain, creating docking sites for downstream signaling proteins. The activated receptor then initiates a cascade of phosphorylation events that propagate the signal inside the cell.
Downstream signaling via PI3K
In simple terms: Activated MET sends signals through PI3K to tell the cell to grow and survive.
One of the major pathways activated by HGF-MET binding is the phosphatidylinositol 3-kinase (PI3K) pathway. Upon MET activation, PI3K is recruited to the receptor and catalyzes the production of phosphatidylinositol-3,4,5-trisphosphate, which in turn activates downstream effectors such as Akt. This signaling axis promotes cell survival, proliferation, and migration, and is frequently dysregulated in cancer.
Regulation by ubiquitination and multimerization
In simple terms: The receptor gets tagged with ubiquitin chains, which control how long the signal lasts.
MET activation is tightly regulated by ligand-induced ubiquitination and multimerization. Upon HGF binding, MET undergoes ubiquitination, leading to the formation of ubiquitin multimers that modulate receptor trafficking and signaling duration. This regulatory mechanism ensures that the signal is transient and prevents excessive activation, and its disruption can contribute to oncogenesis.
Therapeutic targeting of the binding interface
In simple terms: Drugs can block the HGF-MET handshake to stop cancer growth.
Because aberrant HGF-MET binding drives tumor progression, the interaction interface is a prime target for therapeutic intervention. Computational studies have identified novel inhibitors that disrupt the HGF-MET interaction, and phytochemicals such as neogitogenin and samogenin have shown potential for HGF receptor-targeted cancer treatment. Additionally, bacterial agonists of the HGF receptor can stimulate hepatocyte proliferation, offering a strategy for liver regeneration.
Key Genes Involved in GO:0005171 hepatocyte growth factor receptor binding
The following genes and proteins are central to hepatocyte growth factor receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HGF | Encodes hepatocyte growth factor, the primary ligand that binds MET | Target for engineering agonists/antagonists; studied in liver regeneration and cancer |
| MET | Encodes the hepatocyte growth factor receptor, a receptor tyrosine kinase | Central to signaling; mutated or overexpressed in cancers; target for inhibitors |
| PIK3CA | Encodes the catalytic subunit of PI3K, a downstream effector of MET | Mediates survival and proliferation signals; frequently mutated in cancer |
| PIK3R1 | Encodes the regulatory subunit of PI3K | Modulates PI3K activity downstream of MET |
| AKT1 | Serine/threonine kinase activated by PI3K | Promotes cell survival; key node in MET signaling |
| CBL | E3 ubiquitin ligase that ubiquitinates MET | Regulates MET degradation and signaling duration |
| UBB | Encodes ubiquitin, which forms multimers on MET | Essential for MET regulation; studied in receptor trafficking |
| UBC | Encodes ubiquitin C, a ubiquitin precursor | Involved in ubiquitin multimerization on MET |
| FAP68 | FKBP-associated protein of 68 kDa, binds MET in a ligand-regulated manner | Modulates MET signaling; potential target for intervention |
| GAB1 | Docking protein recruited to activated MET | Amplifies PI3K signaling; biomarker in cancer |
| GRB2 | Adaptor protein that binds MET and links to Ras-MAPK pathway | Mediates proliferative signals from MET |
| SRC | Non-receptor tyrosine kinase activated by MET | Contributes to migration and invasion |
| STAT3 | Transcription factor activated by MET signaling | Promotes gene expression for survival and proliferation |
| CDH1 | E-cadherin, involved in cell-cell adhesion modulated by MET | Loss promotes epithelial-mesenchymal transition |
| MMP2 | Matrix metalloproteinase 2, induced by MET signaling | Facilitates invasion and metastasis |
| VEGFA | Vascular endothelial growth factor A, upregulated by MET | Promotes angiogenesis in tumors |
| CCND1 | Cyclin D1, cell cycle regulator induced by MET | Drives proliferation; overexpressed in cancers |
| BCL2 | Anti-apoptotic protein upregulated by MET-PI3K signaling | Contributes to survival; target for therapy |
How Is hepatocyte growth factor receptor binding Regulated?
The binding of hepatocyte growth factor to its receptor is regulated at multiple levels. Ligand-induced ubiquitination and multimerization of MET control receptor internalization, recycling, and degradation, thereby tuning the strength and duration of signaling. Additionally, the interaction is modulated by accessory proteins such as FAP68, which binds MET in a ligand-regulated manner and influences downstream events. Computational studies have also highlighted the importance of specific residues at the binding interface, which can be altered by mutations or targeted by inhibitors.
hepatocyte growth factor receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MET | Cancer (e.g., lung, gastric, renal) | MET knockout or point-mutation cell lines; xenograft models |
| HGF | Liver regeneration failure | HGF overexpression or knockout mouse models; partial hepatectomy |
| MET | Developmental disorders | Conditional knockout mice; zebrafish models |
| CBL | Cancer (dysregulated MET degradation) | CBL knockout cells; ubiquitination assays |
| FAP68 | Cancer (modulated MET signaling) | FAP68 knockdown or overexpression cell lines |
Cancer
Dysregulated HGF-MET binding is a hallmark of many cancers, where autocrine or paracrine HGF production leads to constitutive MET activation, driving proliferation, survival, and metastasis. Overexpression of MET or HGF is associated with poor prognosis in various malignancies, and the binding interface is a target for small-molecule inhibitors and phytochemicals. Computational studies have identified novel therapeutic inhibitors that disrupt the HGF-MET interaction.
Liver disease and regeneration
HGF-MET signaling is critical for liver regeneration after injury or partial hepatectomy. Bacterial agonists of the HGF receptor have been shown to stimulate hepatocyte proliferation and accelerate liver regeneration in a rat model, suggesting therapeutic potential for liver failure. Conversely, impaired HGF-MET binding may contribute to chronic liver disease progression.
Developmental disorders
Given the essential role of HGF-MET signaling in embryogenesis, mutations that impair binding or downstream signaling can lead to developmental defects. Studies in model organisms have elucidated the requirement for this interaction in organ formation, including the liver and placenta.
From hepatocyte growth factor receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MET abolish HGF-induced signaling? | MET knockout cell lines (e.g., CRISPR-Cas9) |
| Does a specific point mutation in MET affect ligand binding? | Point-mutation knock-in cell lines |
| Can a tagged MET be used to track receptor trafficking? | Knock-in of fluorescent or epitope tags |
| Does overexpression of HGF drive tumorigenesis? | HGF overexpression transgenic models |
| What is the role of MET ubiquitination in signaling? | Knock-in of ubiquitin-deficient MET mutants |
| Can bacterial agonists stimulate liver regeneration? | Rat partial hepatectomy model with agonist treatment |
How to Study the hepatocyte growth factor receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Characterizing HGF-MET interaction |
| Isothermal titration calorimetry (ITC) | Thermodynamics of binding | Validating binding interfaces |
| Immunoprecipitation/Western blot | Protein-protein interactions and phosphorylation | Detecting MET activation and downstream signaling |
| Molecular dynamics simulation | Atomic-level interaction dynamics | Predicting inhibitor binding |
| Ubiquitination assays | Post-translational modification of MET | Studying receptor regulation |
| Cell proliferation assays | Cell growth and survival | Evaluating functional outcomes of MET signaling |
| Liver regeneration models | Hepatocyte proliferation in vivo | Testing HGF receptor agonists |
Binding assays
Direct binding between HGF and MET can be measured using surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or enzyme-linked immunosorbent assay (ELISA). These methods provide quantitative data on affinity, kinetics, and the effects of mutations or inhibitors.
Computational modeling
Molecular dynamics simulations and docking studies can predict the HGF-MET interaction interface and identify novel inhibitors. These computational approaches complement experimental validation and accelerate drug discovery.
Signal transduction assays
Downstream signaling events, such as PI3K activation and Akt phosphorylation, can be monitored by immunoblotting, immunoprecipitation, or phospho-specific antibodies. These assays reveal how binding translates into cellular responses.
Ubiquitination and multimerization analysis
Ligand-induced ubiquitination and multimerization of MET can be assessed by immunoprecipitation followed by immunoblotting with ubiquitin-specific antibodies, or by mass spectrometry. These techniques elucidate regulatory mechanisms.
How CRISPR Can Be Used to Study GO:0005171 hepatocyte growth factor receptor binding
Knockout
CRISPR-Cas9 knockout of MET or HGF can completely abolish hepatocyte growth factor receptor binding and downstream signaling, providing a clean background to study the function of the interaction. Such knockout cell lines are valuable for validating specificity of inhibitors and for identifying compensatory pathways.
Point Mutation
Introducing point mutations in the binding interface of MET or HGF can dissect the contribution of individual residues to binding affinity and specificity. For example, mutations identified by computational modeling can be validated using CRISPR-mediated knock-in of point mutants.
Knock-in
Knock-in of tagged versions of MET (e.g., GFP or HA) allows real-time tracking of receptor localization and trafficking upon HGF binding. This approach can also be used to introduce disease-associated mutations or to study ubiquitination site mutants.
Overexpression
Overexpression of HGF or MET using CRISPR activation or lentiviral vectors can mimic the autocrine/paracrine loops seen in cancer and liver regeneration. These models are useful for testing therapeutic inhibitors and agonists.
How EDITGENE Supports hepatocyte growth factor receptor binding Research
Researchers studying hepatocyte growth factor receptor binding-related genes often need to determine whether a candidate gene is causally involved in the binding event or downstream signaling. This requires precise genetic models that can knockout, mutate, or tag the genes of interest. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such studies.
Contact EDITGENE today to design your custom CRISPR model for hepatocyte growth factor receptor binding research.
Frequently Asked Questions About hepatocyte growth factor receptor binding
What is hepatocyte growth factor receptor binding?
It is the molecular function (GO:0005171) of a ligand, primarily hepatocyte growth factor (HGF), binding to the hepatocyte growth factor receptor (MET).
What genes are involved in hepatocyte growth factor receptor binding?
The key genes are HGF, which encodes the ligand, and MET, which encodes the receptor. Other genes such as CBL and FAP68 modulate the interaction.
What is the role of MET in cancer?
MET activation by HGF drives proliferation, survival, and metastasis in many cancers, making it a therapeutic target.
How is hepatocyte growth factor receptor binding regulated?
It is regulated by ligand-induced ubiquitination and multimerization of MET, as well as by accessory proteins like FAP68.
What diseases are associated with hepatocyte growth factor receptor binding?
Dysregulation is linked to cancer, liver disease, and developmental disorders.
Can hepatocyte growth factor receptor binding be targeted therapeutically?
Yes, inhibitors that block the HGF-MET interaction are being developed for cancer treatment.
What methods are used to study hepatocyte growth factor receptor binding?
Common methods include surface plasmon resonance, computational modeling, and cell-based signaling assays.
What is the role of PI3K in hepatocyte growth factor receptor signaling?
PI3K is a major downstream effector that mediates survival and proliferation signals from activated MET.
How does ubiquitination affect hepatocyte growth factor receptor binding?
Ubiquitination of MET controls receptor trafficking and signaling duration, preventing excessive activation.
What CRISPR models are available for studying hepatocyte growth factor receptor binding?
Knockout, point mutation, knock-in, and overexpression models can be generated to study MET and HGF function.
Conclusion
Hepatocyte growth factor receptor binding (GO:0005171) is a fundamental molecular function that initiates MET signaling, a pathway critical for development, tissue regeneration, and cancer progression. Understanding the precise binding mechanism and its regulation has led to therapeutic strategies targeting this interaction. Continued research using advanced CRISPR models and computational approaches will further elucidate its roles and unlock new treatments for related diseases.
References
- 1. Azmal M et al.. 2025. Computational investigation of hepatocyte growth factor receptor-ligand interactions for the identification of novel therapeutic inhibitors.. Comput Biol Med 198(Pt B):111250 PMID: 41138359
- 2. Kawakami N et al.. 2023. MET-Activating Ubiquitin Multimers.. Angew Chem Int Ed Engl 62(36):e202307157 PMID: 37450419
- 3. Galimi F et al.. 1993. The hepatocyte growth factor and its receptor.. Stem Cells 11 Suppl 2:22-30 PMID: 8401259
- 4. Cantley LG et al.. 1995. Signal transduction by the hepatocyte growth factor receptor, c-met. Activation of the phosphatidylinositol 3-kinase.. J Am Soc Nephrol 5(11):1872-81 PMID: 7620084
- 5. Elasbali AM et al.. 2024. Phytochemicals Neogitogenin and Samogenin Hold Potentials for Hepatocyte Growth Factor Receptor-Targeted Cancer Treatment.. OMICS 28(11):573-583 PMID: 39388097
- 6. Bardelli A et al.. 1994. Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.. J Biotechnol 37(2):109-22 PMID: 7765452
- 7. Grisendi S et al.. 2001. Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor.. J Biol Chem 276(49):46632-8 PMID: 11571281
- 8. Kalinin EV et al.. 2021. Bacterial hepatocyte growth factor receptor agonist stimulates hepatocyte proliferation and accelerates liver regeneration in a partial hepatectomy rat model.. Drug Dev Res 82(1):123-132 PMID: 32830369
